newsfilter
← Latest News
GlobeNewswire·

Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis

BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (NASDAQ:AVLN) (Avalyn or the Company), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of